NGL Fine Chem Ltd

- Current CAPEX of approximately Rs. 140 crores is being funded with a debt-to-internal accrual ratio of 2:1 (about 66.7% debt and 33.3% internal accruals). - No explicit mention of new equity fundraising in the call. - Greenfield expansion CAPEX delayed due to commodity price inflation; equipment ordering postponed to Nov 2022 with completion expected by early 2024 and commercial production ramp-up from FY25. - Given the existing debt funding for the CAPEX and the deferred schedule, no immediate new fundraising beyond planned debt is indicated. - Management did not explicitly mention plans for further debt or equity fundraising beyond current projects.

- NGL Fine-Chem is undertaking a greenfield expansion project at Tarapur. - Original CAPEX estimate was Rs. 100 crores, revised to Rs. 140-150 crores due to inflation in raw material and steel prices. - Equipment ordering for the greenfield expansion was initially scheduled for May 2022 but delayed to November 2022 due to high commodity prices. - The new facility construction is expected to complete in early 2024, with commercial production ramp-up anticipated by Q2 FY25. - The expansion is expected to increase capacity by approximately 60%, adding potential revenue of around Rs. 200 crores. - CAPEX funding is planned at a 2:1 debt to internal accruals ratio. - Additional investments include development of 3-4 new products this year, targeting a total product basket of about 30 APIs by 2024. - Price pressures and inflation have delayed the expansion but management is monitoring to accelerate if costs ease.

- NGL Fine-Chem plans to expand its product portfolio to about 30 APIs by 2024 from around 22-23 currently. - The market size for current products is approximately Rs. 1,500 crores, expected to grow to Rs. 2,300-2,500 crores with planned new products. - Three new products in trial runs are anticipated to increase market size by Rs. 800-1,000 crores. - Additional new products planned for this year and next 2-3 years will further expand the market opportunity. - Sales volume growth has been impacted recently due to high prices and demand suppression but is expected to recover by Q4 of the current year. - Capacity expansion (greenfield project) scheduled for commercial operation in FY25 to support higher volumes; capacity to rise by ~60%, adding Rs. 40-50 crores revenue. - Historical market share gains expected to continue, especially in newer products where market share is still growing.

- Revenue growth expected from addition of 3 new products, potentially increasing market size by ₹800-1,000 crores (Page 14). - Plan to expand product portfolio to 30 APIs by 2024, with new products contributing to market expansion (Pages 12-13). - Capacity expansions delayed due to cost overruns and inflation; new greenfield CAPEX expected to complete in early 2024, ramping up revenues from FY25 (Pages 5-6, 10). - Return on capital expected to remain stable over a 3-5 year horizon despite near-term challenges (Page 13). - Current demand and margin pressure expected to ease gradually; gross margins may normalize within 3-4 quarters, with better pricing pass-through (Pages 6-7). - Company aims to maintain leadership in core products and focus on expanding market share in next 10 products (Page 13). - Overall optimism for veterinary pharma industry growth over next 4-5 years despite short-term cyclical challenges (Pages 8-9).

The transcript from the Q1 FY22-23 earnings call of NGL Fine-Chem Limited does not explicitly mention the current or expected order book or pending orders. However, key related highlights include: - Demand is currently subdued due to high prices and customers utilizing old inventory. - Some delay in demand normalization expected—a gentle recovery expected from Q3 FY23, with stronger recovery anticipated in Q4 FY23. - Pricing pressure and inflation have caused customers to resist price hikes, impacting orders. - A US customer places semi-annual orders; one shipment scheduled in Q2 FY23. - New products are under trial, expected to expand market size and order potential by Rs. 800 to 1,000 crores. - Capacity utilization is currently around 70%, with plans for expansion by FY25. No specific quantitative order book or pending order figures disclosed.